EMA Authorised: Riulvy (tegomil fumarate) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

EMA authorised Riulvy (tegomil fumarate) for relapsing-remitting multiple sclerosis, with Neuraxpharm Pharmaceuticals S.L. as the marketing authorization holder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Riulvy (tegomil fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 23/09/2025